



Inflation Reduction Act

Preparing for Medicare Drug Pricing

Agenda

- The Basics of the Medicare Drug Price Negotiations
- Medicare Transaction Facilitator (MTF) Enrollment
- Maximum Fair Price (MFP) data and cash flow
- Take Aways





Key Abbreviations

DDPS	Drug Data Processing System
MFP	Maximum Fair Price
MTF	Medicare Transaction Facilitator
MTF DM	Medicare Transaction Facilitator Data Module
MTF PM	Medicare Transaction Facilitator Payment Module
PDE	Prescription Drug Event
SDRA	Standard Default Refund Amount
WAC	Wholesale Acquistion Cost





The Basics

 Provisions addressing the cost of drugs paid by Medicare is part of The Inflation Reduction Act which was signed into law on August 16, 2022

Effective Year	Provision	Medicare Payer
2023	Inflation Rebates, \$35 Insulin Copay Cap, elimination of cost sharing on vaccines	Medicare Part B & D
\$2,000 out-of-pocket cap	2025	Medicare Part D
Medicare Drug Price Negotiation	2026	Medicare Part B & D for high-cost drugs





Medicare Drug Price Negotiation

- Beginning January 1, 2026
- The first 10 MFP on negotiated drugs goes into effect
- Only applies to Medicare part D for 2026 & 2027
- Part B will be added starting in 2028





What is Maximum Fair Price (MFP)?

- Select single-source biologics or brand-name drugs
 - Generics are not included
- Small molecular drugs must have been on the market for at least 9 years
- Biologics must have been on the market for at least 13 years
- The drugs must have had a high Medicare spend in the previous 12 months





MFP....

The number of drugs affected

Year	Number of Total Drugs
2026	10
2027	25
2028	40
2029	60
2023	80

• Shown are the number of drugs. All strengths and package size are affected

Affected Drugs in 2026

Drug	Manufacturer
Eliquis	Bristol-Myers Squibb
Enbrel	Amgen
Entresto	Novartis
Farxiga	AstraZeneca (& Prasco)
Imbruvica	AbbVie
Januvia	Merck
Jardiance	Boehringer Ingleheim
Novolog/FIASP	Novo Nordisk
Stelara	Johnson & Johnson
Xarelto	Johnson & Johnson





How Does MFP Affect 340B?

- IRA: Section 1193 in layman's terms
 - Beginning January 1, 2026, Medicare Part D payment will not exceed the MFP for the negotiated drugs
 - 340B Covered Entities get the lower of the 340B price or the MFP.





Reimbursement....

- If a drug has a negotiated MFP, Medicare Part D will reimburse at the MFP
 - 340B Covered Entity purchase at the lower of the two prices
 - Generally, 340B price will be at or below the MFP






Medicare Transaction Facilitator (MTF)

- Phase II: Enrollment
 - June December 2025
 - CMS lauch of MTF data module (MTF DM)
 - Dispensing Entities able to enroll



NCPDP: Validate Your Information







MTF Enrollment

 https://links-2.govdelivery.com/CL0/https:%2F%2Fmtf.cms.gov%2Fmtfdm%2F login/1/0101019953e26518-029a1330-aa71-47f8-a1df-31354d660e82-000000/kImd1XCStCNe-axS4yS2PhXxyh36bxBhkUAF330uOE=423



Welcome to the Medicare Transaction Facilitator (MTF)

Sign in to the MTF to enroll your organization, invite additional users to create their own profiles, and access key features designated for manufacturers, dispensing entities, and third-party support entities.

Already have CMS Identity Management (IDM) credentials? You can use them to sign in and set up your profile immediately.

Learn more about the MTF by visiting the Medicare Drug Price

Negotiation section of the CMS website.

Password	ı
	•
By signii	ng in to the MTF, you agree with our Terms & Conditions
	Sign in
Forgot Use	er ID?
Forgot Use	





MTF pulls pharmacy Information from the NCPDP Portal







MTF DM Dispenser Enrollment

- Section 1
 - o Entity User Roles
 - Authorized Signatory Official (AO)
 - Can legally bind the organization
 - Access Manager: Designated by the AO
 - View, modify, submit and certify the completeness and accuracy of the information
 - Staff End User:
 - Limited to submitting complaints and disputes
 - Can view and download information



MTF DM Dispenser Enrollment

- Section 2
 - Entity Identification Information
 - Option 1
 - Use the information found on the NCPDP
 - This helps make the enrollment procedure more efficient and accurate
 - Option 2
 - Manual entry



Self-Identified Cashflow Concerns

- Per CMS, Pharmacies most likely to be impacted
 - Sole proprietor rural or urban pharmacies with high Medicare Part D prescription volume
 - Pharmacies relying predominantly on Medicare prescription revenue
 - Log term care pharmacies
 - 340B Covered Entities



Cashflow Concerns

- Question will be asked do you expect a cashflow problem
 - O How will you answer this question for your organization?
 - o If Yes
 - You will need to enter your Pharmacy (ies) NPI
 - Download the excel document
 - Enter all the NPI numbers
 - Upload the completed document





Section 3: Dispensing Entity Financial Information

- Payments Received through PSAOs
 - You will be required to provide your banking information even if you elect to be paid through your PSAO (electronic or paper check)
 - You will need
 - Bank Name
 - Account Name
 - Account type (Checking or Savings)
 - Account Number
 - Routing Number
 - A Bank letter or a voided check
 - Bank letter must have all the above data points and be signed by a bank official
 - Employer Identification Number (EIN)



Section 4: Dispensing Entity MFP Refund Payment Instructions for Primary Manufacturers Not Participating in the MTF PM

 Acknowledge and agree to sharing your financial information with those manufacturer's not participating in MTF PM



MTF DM Dispenser Enrollment

Section 5

- Entity Contact Information
 - Primary and Secondary Point of Contact

Section 6

- Entity Certification
 - Equivalent to CEO or CFO or someone who had been delegated the authority to certify



MTF: Call Helpline

Toll-Free: 877-683-4457 (877-MTF-4HLP





Payment Process

- Pharmacy purchases the drug at the retail price
- Pharmacy submits MFP claim to Medicare Part D Plan
- Plan pays reimbursement of MFP plus the dispensing fee, along with anticipated Standard Default Refund Amount (SDRA)
 - SDRA is the difference from the warehouse acquisition cost and maximum fair price
- Data received by the MTF and transmits it to the Manufacturer
- Manufacturer determines the MFP refund amount and refunds the pharmacy within 14 days
 - There is no refund for 340B eligible claims if the 340B cost is lower than
 MFP



Evaluating the Impact at the NDC level

- 80% of the negotiated NDC numbers have MFP higher than 340B pricing
 - 70% still allow for margin
 - 10% are neutral
- 20% of the negotiated NDC number have MFP lower than 340B pricing
 - Most likely these NDCs will not be winners through contract pharmacy relationships



Options for the Health Center

- 1. Take the loss
- 2. Switch to another treatment option
 - Not always feasible
 - Possible for some disease states like diabetes
 - May be tricky to just do this for Medicare patients
 - This would require provider cooperation





Options.....

- Open an in-house pharmacy
 - It has been shown that revenue can be as much as 15 times higher when prescriptions are filled at entity-owned pharmacies verses contract pharmacies.
 - Most medications will contribute net margins
 - MFP will still impact revenue but will allow net margins on most negotiated drugs.
 - Even if the MFP is lower than 340B it will still yield a dispensing fee.
 - The pharmacy will be made whole
 - Improved patient access



David Christian

Pharmacy Director
Central Virginia Health Services, Inc.

rx@cvhsinc.org

Office: 434-581-3271 x 10513

Mobile 434-390-8788



